• Galatea Bio, Fabric Genomics Combine Pathogenic Variant Analysis with Polygenic Risk Score

    Jun 26 | Diagnostics World | Galatea Bio and Fabric Genomics announced a strategic collaboration this week to enhance genetic testing by incorporating both rare pathogenic variant analysis and polygenic risk scoring (PRS) to assess genetic susceptibility to common diseases. More

  • Follow the Money: Neuroplastogens Novel Therapies, Genetic Medicines, More

    Jun 25 | Diagnostics World | Elkedonia SAS plans to develop the drug-like small molecule inhibitors of Elk1, a novel intracellular target that plays a pivotal role in reward brain circuits and neuroplasticity; SpliceBio will advance the clinical development of their lead gene therapy candidate, SB-007, for Stargardt disease; and more. More

  • Veeva, Sarah Cannon Research Institute Collaboration, City of Hope Receives Grant, More

    Jun 24 | Diagnostics World | Veeva and Sarah Cannon Research Institute has entered a strategic collaboration; City of Hope was awarded an up to $23.7 million contract from the Advanced Research Projects Agency for Health within the US Department of Health and Human Services; and more. More

  • Nanoneedle Technology Could Transform Medical Diagnostics

    Jun 20 | Diagnostics World | Researchers at King's College London have developed a diagnostic tool that could enable doctors to sample tissue during critical medical procedures. The nanoneedle patch technology enables physicians to extract molecular information from living tissue without causing damage or killing cells—a capability that could prove especially valuable in delicate surgical situations. More

  • Real-time Molecule Monitoring Could Put an End to ‘Reactive Medicine’

    Jun 17 | Diagnostics World | Modern jet engines can generate a terabyte or more of data per hour that gets transmitted back to the engine manufacturer to ensure aircraft safety and prevent disasters from happening. Yet the human body, arguably the most important machinery of them all, gets checked only once a year or whenever something has already gone wrong. More

  • Myeloma Diagnostics: Ultra-Sensitive Detection and Population-Scale Screening Transform Disease Management

    Jun 12 | Diagnostics World | The International Myeloma Foundation's Black Swan Research Initiative is changing how multiple myeloma is detected, monitored, and managed. From single-cell detection technologies to population-scale screening programs, these advances are setting new standards for precision oncology diagnostics. More

  • Pharmacogenomic Testing Shows Value in Improving Prescribing Precision

    Jun 11 | Diagnostics World | After the human genome was sequenced in 2003, expectations were high that it would drive direct and immediate benefits for the everyday healthcare of the general population. While genomics has fundamentally altered the clinical pathways for individuals with rare diseases and cancer, it has yet to become part of routine clinical practice. More

  • Endometriosis Developments: Newly Launched Tests and Treatment Updates

    Jun 10 | Diagnostics World | Endometriosis occurs when tissue similar to the lining of the uterus grows outside of the uterus. The condition is painful, can impede fertility, and is difficult to diagnose. But a host of new tools seek to improve diagnostics and treatment for the condition. More

  • Genetic Diagnostics Find Common Ground Between ME/CFS, Long COVID

    Jun 05 | Diagnostics World | PrecisionLife's new diagnostic approach is addressing a critical gap in complex chronic disease detection by targeting two genetically related conditions that share remarkable similarities. Long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) are not just clinically similar—they're genetically connected, with researchers identifying nine genes common to both disease populations. More

  • After More Than Four Decades, a Third Subtype of Castleman Disease Found

    Jun 03 | Diagnostics World | A new subtype of Castleman disease has been identified, the first such major discovery in 45 years. While it remains unclear how many individuals stand to benefit, this is a “hugely important” development for the proportion of patients who fit neither the “unicentric” nor “multicentric” criteria long used to describe the symptoms and disease experience. More
View more articles

 
DXX-Industry-spotlight

merck


Custom Diagnostic Antibody Development & Manufacturing Services

Overcome Process Challenges by outsourcing your custom antibody production to us. How partnering with an antibody production expert can improve your assay, accelerate launch, and maintain your manufacturing.

Learn more